Influence of COVID-19 on immune responses to pneumococcal Polysaccharide and influenza vaccinations in older persons - COVID-19 influence on pneumococcal vaccine responsiveness in elderly

RIVM0 sites600 target enrollmentTBD

Conditionsvaccinatie tegen pneumokokken (bacterële infectie), en tegen griep (virale infecties), immuunsysteem COVID-19 vaccination response

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: vaccinatie tegen pneumokokken (bacterële infectie), en tegen griep (virale infecties), immuunsysteem
Sponsor: RIVM
Enrollment: 600
Status: Withdrawn
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Observational invasive

Investigators

Sponsor

RIVM

Eligibility Criteria

Inclusion Criteria

•\-Born between 1941\-1947 (73\-79 years of age)
•\-COVID\-19 group: Having had a proven (SARS\-CoV\-2 PCR test positive) COVID\-19
•infection at least 1 month before study entry
•\-Control group: Have not had a positive SARS\-CoV\-2 PCR test
•\-Willing to receive the PPV23 vaccine
•\-Be capacitated
•\-Have signed Informed Consent

Exclusion Criteria

•\-Having had a previous pneumococcal vaccination (PCV or the 23\-valent
•pneumococcal polysaccharide vaccine (PPV23\)).

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting

Phase 1

Impact of the immune system on response to COVID-19 vaccine in allogeneic stem cell recipientsAllogeneic hematopoietic stem cell recipientsTherapeutic area: Body processes [G] - Immune system processes [G12]

EUCTR2021-000673-83-BECHU de Liège70

Recruiting

Not Applicable

Impact of COVID-19 Pneumonia on Pulmonary Function, Exercise capacity, Mood disorders, and Quality of Life in Long-term Follow UpPost discharge all subjects with SAR-COV-2 (COVID-19 virus) pneumoniaCOVID,pneumonia,exercise capacity,lung function,mood disorders

TCTR20210827005Faculty of Medicine, Chiang Mai University72

Active, not recruiting

Phase 1

Humoral (antibodies) and cellular (white blood cells) immune response to COVID-19 vaccines in immunocompromised (people with impaired immune system) and healthy individuals – The CoVVac studyActive immunisation to prevent COVID-19 in immunocompromised individuals.MedDRA version: 23.1Level: PTClassification code 10084457Term: COVID-19 immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Health Care [N] - Population Characteristics [N01]

EUCTR2021-001040-10-ATMedical University of Graz390

Completed

Not Applicable

Investigating the immune response to COVID-19 vaccination in lung transplantation patients (COVALENT study)

NL-OMON22289niversity Medical Center Groningen (UMCG)180

Not yet recruiting

Not Applicable

Effect of COVID-19 vaccination in Rheumatoid arthritis patientsHealth Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified

CTRI/2021/09/036579AIIMS Bibnagar